Book contents
- Managing Discovery in the Life Sciences
- Managing Discovery in the Life Sciences
- Copyright page
- Contents
- List of Figures
- List of Tables
- Preface
- 1 Discoveries Now and Then
- 2 Pharma Trends
- 3 Profit-Maximizing Drug Firms
- Transitional Note: Introduction to the Case Studies
- 4 The Statins
- 5 ACE Inhibitors
- 6 Angioplasty
- 7 Hepatitis C
- 8 Alzheimer’s
- 9 Metformin
- 10 Medical Genomics
- 11 Gleevec
- 12 Regeneron
- 13 Avastin and Lucentis
- 14 CAR T-Cell Therapy
- 15 Organizing Discovery
- 16 Can Government Help with the Creatively Unexpected?
- Appendix Key Elements in the Discovery Process: Historical and Philosophical Antecedents
- Index
Transitional Note: Introduction to the Case Studies
Published online by Cambridge University Press: 19 January 2018
- Managing Discovery in the Life Sciences
- Managing Discovery in the Life Sciences
- Copyright page
- Contents
- List of Figures
- List of Tables
- Preface
- 1 Discoveries Now and Then
- 2 Pharma Trends
- 3 Profit-Maximizing Drug Firms
- Transitional Note: Introduction to the Case Studies
- 4 The Statins
- 5 ACE Inhibitors
- 6 Angioplasty
- 7 Hepatitis C
- 8 Alzheimer’s
- 9 Metformin
- 10 Medical Genomics
- 11 Gleevec
- 12 Regeneron
- 13 Avastin and Lucentis
- 14 CAR T-Cell Therapy
- 15 Organizing Discovery
- 16 Can Government Help with the Creatively Unexpected?
- Appendix Key Elements in the Discovery Process: Historical and Philosophical Antecedents
- Index
Summary
- Type
- Chapter
- Information
- Managing Discovery in the Life SciencesHarnessing Creativity to Drive Biomedical Innovation, pp. 73 - 74Publisher: Cambridge University PressPrint publication year: 2018